Anti-PD1-R checkpoint inhibitor related severe relapsing myelitis

Affiliations

¹ Neurology Department, Saint Antoine Hospital, APHP, Sorbonne Université, Paris, France.
² Service de médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU i3D), Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France.
³ Radiology Department, Saint Antoine Hospital, APHP, Sorbonne Université, Paris, France.
⁴ Service de médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU i3D), Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France. arsene.mekinian@aphp.fr.

Case Reports

Edouard Januel et al. Acta Neurol Belg. 2021 Dec.

. 2021 Dec;121(6):1855-1857.

doi: 10.1007/s13760-020-01434-y. Epub 2020 Jul 13.

¹ Neurology Department, Saint Antoine Hospital, APHP, Sorbonne Université, Paris, France.
² Service de médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU i3D), Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France.
³ Radiology Department, Saint Antoine Hospital, APHP, Sorbonne Université, Paris, France.
⁴ Service de médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU i3D), Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France. arsene.mekinian@aphp.fr.

No abstract available

References

1. Sato K, Mano T, Iwata A, Toda T (2019) Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. J Neurooncol 145:1–9 - DOI
1. Anderson D, Beecher G, Nathoo N, Smylie M, McCombe JA, Walker J, Jassal R (2019) Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors. Neurooncol Pract 6:340–345 - PubMed
1. Shi J, Niu J, Shen D, Liu M, Tan Y, Li Y, Huang Y, Cui L, Guan Y, Zhang L (2020) Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related adverse reactions in the nervous system. Thorac Cancer 11(2):481–487 - DOI
1. Narumi Y, Yoshida R, Minami Y, Yamamoto Y, Takeguchi S, Kano K, Takahashi K, Saito T, Sawada J, Terui H, Katayama T, Sasaki T, Ohsaki Y (2018) Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. Case Reports 18(1):95
1. Tauber M, Cohen R, Laly P, Josselin L, André T, Mekinian A (2019) Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy. Clin Rheumatol 38(2):601–602 - DOI